A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease

BMC Nephrology

Table 3 Evolution of eGFR and BMI over 24 months of treatment in intention-to-treat and per-protocol population

No. of patients	Study period	Mean eGFR value (ml/min/1.73m²)	Mean eGFR change (ml/min/1.73m²)	95% CI	P Value	Mean BMI Value (kg/m²)	Mean BMI change (kg/m²)	95% CI	P Value
A. Mean eGFR and BMI changes in intention to treat population
34	Baseline	60.45 ± 34.71	–	–	–	27.10 ± 3.65	–	–	–
28	1 month	61.41 ± 34.17	0.96	−16.63 to −18.55	0.91	26.94 ± 3.58	−0.16	−2.00 to 1.68	0.86
25	4 months	62.16 ± 34.53	1.71	−16.56 to 19.98	0.85	26.45 ± 3.48	− 0.65	− 2.53 to 1.23	0.49
20	12 months	59.42 ± 37.67	−1.03	− 21.28 to 19.22	0.91	26.27 ± 3.32	−0.80	−2.82 to 1.16	0.40
16	24 months	58.88 ± 32.32	−1.57	−22.28 to 19.14	0.87	26.00 ± 3.07	−1.10	−3.22 to 1.02	0.30
B. Mean eGFR and BMI changes in per protocol population
16	Baseline	63.45 ± 32.68	–	–	–	26.80 ± 3.76	–	–	–
16	1 month	64.83 ± 31.68	1.38	−21.85 to 24.61	0.90	26.56 ± 3.82	−0.24	−2.97 to 2.49	0.85
16	4 months	65.26 ± 30.65	1.81	−21.60 to 24.68	0.87	26.34 ± 3.60	−0.46	−3.11 to 2.19	0.76
16	12 months	62.80 ± 34.58	−0.65	−24.94 to 23.64	0.95	26.31 ± 3.46	−0.49	− 3.09 to 2.11	0.70
16	24 months	58.88 ± 32.32	− 4.57	−28.03 to 18.89	0.69	26.00 ± 3.07	−0.80	−3.27 to 1.67	0.51

No. number, CI confidence interval, eGFR estimated glomerular filtration rate, BMI body mass index

ISSN: 1471-2369